Advisory Panel on COVID-19 Vaccines <u>Summary of Declaration of Interests by Members</u>

(Position as at 27 August 2021)

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|-------|---------------------|--|--|---|-------------------------------|
| | | Nil | | Nil | Nil |
| | Chak-sing, Wallace, | | Professor, Division of | | |
| | JP | | Rheumatology and Clinical | | |
| | | | Immunology, Department of | | |
| | | | Medicine, HKU | | |
| | | | 2. Head, Department of | | |
| | | | Medicine, HKU | | |
| | | | 3. Chief of Service, Department | | |
| | | | of Medicine, Queen Mary | | |
| | | | Hospital | | |

| | vacations | or private (1% or more of the company's issued share capital) | |
|---|-------------------|--|--|
| ng Kong cs Society member of inese ita Research tion member of ng Kong ist Medical tion n-chief of ournal of ology and cs | ospital Authority | Nil | Nil |
| i tali o | ong Kong H | member of ong Kong Hospital Authority 2. Part-time lecturer, CUHK member of ong Kong in Research ong Kong ist Medical on on-chief of ournal of clogy and one organisations | member of ong Kong ics Society inesse tia Research attion in-chief of ology and ics so organisations in the second ics i |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|---------------------------|--|---|--|---|
| | | sponsorships for the purpose of continuous medical education from various pharmaceutical companies including Pfizer and AstraZeneca. | | | |
| Member | Professor Keiji FUKUDA | Nil | Director, School of Public Health, Li Ka Shing Faculty of Medicine, HKU | Nil | Nil |
| Member | Professor LAU Yulung, JP | 1. Founder and Committee Member, Children's Catastrophic Disease Foundation 2. Executive Committee Member, Society for | Chair Professor, Department of Paediatrics & Adolescent Medicine, HKU | Nil | Principal Investigators for multiple industry-sponsored vaccine trials over many years mainly with GSK. As Founding President of Asia Pacific Society for |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|----------------|---|--|---|--|
| | | the Relief of Disabled Children 3. Founder and Board of Governors Member, Children's Thalassaemia Foundation 4. Founding President, Asia Pacific Society for Immunodeficiencies | | | Immunodeficiencies, sponsorship from various pharmaceutical companies, in particular CSL Behring, have been received. |
| Member | Dr HO King-man | Serve in the Council of the HK College of Dermatologists, HK Society for Paediatric Dermatology, Association for | Ad hoc teaching in courses organized by HKU, PolyU, CUHK | Nil | Currently serves in the Councils of the following professional associations: 1. HK Society for Paediatric Dermatology |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|-------|------|--|--|---|----------------------------|
| | | Integrated Aesthetic | | | (non-profit making |
| | | Medicine, and Asia | | | organization) |
| | | Dermatological | | | 2. HK College of |
| | | Association | | | Dermatologists (non- |
| | | | | | profit making |
| | | The above organisations | | | organization) |
| | | might have received | | | 3. Asian Dermatological |
| | | sponsorships from | | | Association (non-profit |
| | | various pharmaceutical | | | making organization) |
| | | companies including | | | 4. Association for |
| | | Pfizer (but never | | | Integrative Aesthetic |
| | | SinoVac) in educational | | | Medicine, HK (in the |
| | | events or activities. | | | process of application |
| | | Dr HO have not | | | for non-profit making |
| | | received any | | | organization) |
| | | remuneration from these | | | |
| | | services in these | | | These professional |
| | | Society/Associations. | | | associations may organize |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|-------|------|--|--|---|-------------------------------|
| | | | | | educational activities for |
| | | | | | local doctors or healthcare |
| | | | | | professionals and the |
| | | | | | industry may sponsor |
| | | | | | overseas or local speakers |
| | | | | | to deliver lectures or set up |
| | | | | | exhibition booth in these |
| | | | | | activities. As far as |
| | | | | | Dr HO knows, Pfizer, |
| | | | | | Astrazeneca, BioNtech, |
| | | | | | and Sinovac seldom, if |
| | | | | | any, sponsor or set up |
| | | | | | booth in educational |
| | | | | | activities organized by |
| | | | | | these associations. |
| | | | | | Dr HO has not received |
| | | | | | any remuneration by |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|---------------------------------|--|--|---|--|
| | | | | | serving in the Councils of these professional associations. Asian Dermatological Association will sponsor one night hotel accommodation for him to attend the Annual General Meeting should it be organised in cities outside Hong Kong. The sponsorship is derived from the internal resource of the Association. |
| Member | Professor HUI Shucheong, David, | Nil | An advisor to Roche on clinical research related to Baloxavir for treatment of influenza | Nil | Chairperson of the organising committee for the "CUHK Advances in |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|----------------------------------|--|--|---|--|
| | BBS | | | | Medicine annual conference" and organising committee for the "Hong Kong Thoracic Society annual scientific meeting and autumn respiratory seminar" |
| Member | Professor HUNG Fan-ngai, Ivan | Nil | Nil | Nil | Received honoraria as Advisory Board Member for Pfizer, Roche, AstraZeneca, MSD, Abbvie, Ferring, Gilead and Chong Lap |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|-------------------|--|--|---|-------------------------------|
| Member | Professor Gabriel | Nil | Dean of the Faculty of Medicine | Nil | 1. Serve on the Health |
| | Matthew LEUNG, | | of HKU which has one COVID- | | Committee of the Belt |
| | GBS, JP | | 19 vaccine under development | | and Road General |
| | | | | | Chamber of Commerce, |
| | | | | | in which one of the |
| | | | | | committee members is |
| | | | | | the Executive Director |
| | | | | | of Sino |
| | | | | | Biopharmaceutical |
| | | | | | Limited, a listed |
| | | | | | company in Hong Kong |
| | | | | | which had bought a |
| | | | | | significant stake in |
| | | | | | Sinovac Biotech |
| | | | | | Limited (Sinovac) |
| | | | | | 2. According to |
| | | | | | Prof LEUNG's |
| | | | | | understanding, |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|--|--|--|---|---|
| | | | | | BioNTech vaccine has no relation with Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong"). However, he would like to declare that he has a professional acquaintance with the Country Manager of Pfizer Hong Kong for a long time |
| Member | Professor LIANG Hin-suen, Raymond, SBS, JP | Hong Kong Medical Museum Hong Kong Marrow Match Foundation Hong Kong Blood Cancer Foundation | Hong Kong Sanatorium & Hospital (HKSH Medical Group) | Nil | Nil |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|--------------------------------|--|--|---|---|
| | | 4. Hong Kong Academy of Medicine Foundation Fund | | | |
| Member | Dr TSANG Ho-fai, Thomas | Nil | Nil | Nil | Pfizer is one of the sponsors for Annual Scientific Meetings of the Hong Kong College of Community Medicine of which Dr TSANG is the current President. |
| Member | Professor WONG Chi-kei, Ian | Independent non- executive director of Jacobson (Hong Kong) since 2017 Director of Healthcare Innovation | Lo Shiu Kwan Kan Po Ling Endowed Professor in Pharmacy and Head of Department of Pharmacology & Pharmacy, HKU Chair Professor of Pharmacy Practice and Medicine | Therakind Limited (UK) | 1. Lead Scientist in Research Programme 4. Laboratory of Data Discovery for Health Limited (D24H). InnoHK since November 2020 |

| Panel Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|------------|--|---|---|---|
| | Technology Service (London) since 2007 | Evaluation Research, University College London (UCL) School of Pharmacy, London | | Member of Independent Scientific Advisory Committee (ISAC) for Clinical Practice Research Datalink (CPRD) of UK Medicines and Healthcare Products Regulatory Agency (2016-2021) Co-Director of Centre for Medication Optimisation Research and Education at the University College London Hospital (Since) |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|-------|------|--|--|---|------------------------------|
| | | | | | 4. Specialist Advisor to |
| | | | | | NPS Medicinewise in |
| | | | | | Australia on |
| | | | | | MedicineInsight (since |
| | | | | | 2018) |
| | | | | | 5. Member of Hong Kong |
| | | | | | Pharmacy and Poisons |
| | | | | | Board (Regulatory |
| | | | | | Authority in Hong |
| | | | | | Kong) (since 2018) |
| | | | | | 6. Consultant to IQVIA |
| | | | | | (since 2018) |
| | | | | | 7. Principal investigator of |
| | | | | | "COVID-19 Vaccines |
| | | | | | Adverse Events |
| | | | | | Response and |
| | | | | | Evaluation (CARE) |
| | | | | | Programme" funded by |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|--------|---|--|---|---|--|
| | | | | | the Food and Health Bureau |
| Member | Professor YUEN Kwok-yung, GBS, JP | 1. Managing Director of Centre for Virology, Vaccinology and Therapeutics Limited 2. Director of The Hong Kong Academy of Sciences | Clinical Professor (Chair of Infectious Diseases), Department of Microbiology, HKU Service Director (Path), Hong Kong West Cluster, Hospital Authority | Nil | 1. Collaborations with the Wantai pharmaceutical/Xiamen University and the Changchun Bai Kai, BCHT (長春百克) pharmaceutical in the phase 1 clinical trial for the HKU intranasal Covid-19 vaccine 2. Collaboration with the company that manufactures the |

| Panel | Name | Proprietorships, partnerships or directorships of companies, public or private | Remunerated employments, offices, trades, professions or vacations | Shareholdings in companies, public or private (1% or more of the company's issued share capital) | Other declarable interests |
|-------|------|--|--|--|---|
| | | | | | intramuscular ICCOV DNA vaccine: 广州白 云山拜迪生物医药有 限公司 Guangzhou Baiyunshan Baidi Biotechnology Co., Ltd |